Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F. Morand, Raj Tummala, Richard Furie et al.|New England Journal of Medicine|2019Cited by 1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Andrea Doria et al.|Annals of the Rheumatic Diseases|2023Cited by 913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisTsutomu Takeuchi, Takayoshi Koike, Yoshihiko Tatsuki et al.|Annals of the Rheumatic Diseases|2007Cited by 413
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Marta Mosca, Ian N Bruce et al.|The Lancet|2023Cited by 164
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth Kalunian, Hussein Al‐Mossawi, Richard Furie et al.|Arthritis & Rheumatology|2022Cited by 151